Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC vs Oral Thalidomide and Capecitabine in Unresectable HCC
NCT02240771Phase 3Unknown
- Sponsor
- AIIMS New Delhi
- Start
- Jan 2006
- Primary completion
- Dec 2014
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin, cisplatin, thalidomide, capecitabine in hepatocellular carcinoma (HCC), sponsored by AIIMS New Delhi. Status: unknown.
02
Drugs
doxorubicincisplatinthalidomidecapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02240771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240771.